Seelos Therapeutics announced that it has retained Canaccord Genuity to assist in its ongoing review of potential partnerships, collaborations, and similar opportunities.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SEEL:
- Empery alleges critical clinical trial misrepresentations by Seelos Therapeutics
- Seelos Therapeutics reports preclinical data from an in vivo study of SLS-005
- Biotech Alert: Searches spiking for these stocks today
- Enphase Energy upgraded, Brighthouse downgraded: Wall Street’s top analyst calls
- Seelos downgraded to Neutral at Guggenheim after SLS-002 trial misses endpoint
